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esponsibility of InstAbstract The present work compares and evaluates the suitability of different polymer-based
microparticles for inhalation delivery of doxycycline hyclate. Mucoadhesive polymers, such as sodium
carboxymethyl cellulose, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, starch, and carbopol
were selected as carriers for inhalation delivery. Microparticles were prepared by spray drying and
evaluated in terms of yield, moisture content, morphology, tapped density, encapsulation efﬁciency,
in vitro mucoadhesion, thermal properties and in vitro aerosolization performance. Additionally, the
cytotoxicity of the microparticles on H1299 human alveolar cell line was examined. Smooth spherical to
collapsed doughnut shaped particles were formed. They exhibited tap densities of 0.202–0.502 g/cm3 and
mass median aerodynamic diameter of 3.74–6.54 mm. Mucoadhesion was highest in case of carbopol-
based microparticles. Drug release from these microparticles exhibited biphasic Fickian type of diffusion.
Only at the highest concentration of microparticles (1 mg/mL) less than 90% cell viability was seen in DX
loaded sodium alginate microparticles (DXSA, 87.2%), starch microparticles (DXST, 85.1%) and
carbopol microparticles (DXCP, 82.7%) preparations after 48 h of exposure to alveolar cells. The results
clearly indicate that sodium carboxymethyl cellulose-based microparticles may serve as an ideal carrier for
inhalation delivery of doxycycline hyclate.
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Doxycycline hyclate (DX) is a tetracycline derivative effective
against a wide variety of respiratory pathogens such as Staphy-
lococcus aureus,Hemophilus inﬂuenzae, Streptococcus pneumoniae
and Mycoplasma pneumonia by inhibition of the translation
step in protein synthesis1. A signiﬁcant advantage of DX is its
activity against tetracycline-resistant S. aureus. At present, DX is
administered orally and parenterally and is associated with dose-
dependent side effects2, such as oesophageal ulceration, photo-
sensitivity, anaemia, teratogenecity, hepatotoxicity and gastro-
oesophageal reﬂux disease on chronic use. DX is readily
absorbed, widely distributed, and eliminated in urine. Recently,
its activities against matrix metalloproteinase3 have been applied
to the reduction of inﬂammatory changes associated with
asthma, cystic ﬁbrosis and chronic lung diseases. However, one
of the major drawbacks in the treatment of lung infections by
conventional routes of administration is that only 5–10% of the
antibacterial reaches the target site.
Among the different routes of drug administration, inhalation
delivery of antibacterials is of recent interest. Compared to oral
or parenteral delivery, much higher pulmonary drug concentra-
tion can be achieved via inhalation route. This non-invasive route
circumvents ﬁrst-pass metabolism and systemic toxicity. How-
ever, the therapeutic beneﬁt of many inhaled drugs currently on
the market is often short-lived. It is obvious that there has been a
growing desire to prolong the duration of therapeutic action of
these drugs. In recent years, there has been considerable interest
in the development of polymeric carriers for inhalation drug
delivery. One strategy with potential implications for inhalation
delivery is the use of microparticulate drug delivery systems that
intrinsically incorporate a mucoadhesive agent in the formula-
tion. These mucoadhesive agents are typically high molecular
weight polymers which can interact with the mucin layer of the
respiratory epithelium through hydrogen bonding, electrostatic,
hydrophobic or van der Waals interactions. Mucoadhesive
microparticles designed for inhalation delivery should be
typically in the size range 1–5 mm. The incorporation of
antibacterials into these polymeric matrices modiﬁes the drug
pharmacokinetics by increasing lung residence, area under the
concentration time curve and decreasing the apparent volume of
distribution4. It is expected to improve the therapeutic index
compared with free antibacterials. Although the concept of
mucoadhesion at the upper respiratory tract has been broadly
studied5–7, application to the lower respiratory tract has not been
explored. Mucoadhesive polymers such as hydroxypropyl cellu-
lose8, chitosan9, poly(lactic acid)10, poly(D,L-lactic-co-glycolic
acid)11, carbomer12 and sodium carboxymethyl cellulose13 have
been studied by various researchers for inhalation drug delivery.
While the safety of some carriers has been examined in different
routes of drug administration, extensive toxicological studies are
required before more mucoadhesive carriers are used in clinical
practice for inhalation delivery.
In the present study, mucoadhesive polymers were selected as
potential carriers for inhalation drug delivery. Microparticles
were prepared by spray-drying. The aim of the present work
was to compare and evaluate the suitability of different
polymer-based microparticles for inhalation delivery of DX.
The prepared microparticles were evaluated in terms of yield,
moisture content, particle morphology, tap density, encapsula-
tion efﬁciency, in vitro mucoadhesion, thermal properties and
in vitro aerosolization performance. Additionally, thecytotoxicity of the mucoadhesive polymers on H1299 human
alveolar cell line was compared with sodium lauryl
sulphate (SLS).2. Materials and methods
DX was obtained as a gift sample from Ranbaxy Research
Laboratories Ltd. (Gurgaon, India). Sodium alginate (MW
216 Da), polyvinylpyrrolidone K90 (MW 700,000 Da) and
carbopol 974P (MW 300,000 Da) were purchased from ISP
Inc. (Canada), BASF AG (Ludwigshafen, Germany) and B.F.
Good Rich Ltd. (Cleveland, OH), respectively. Sodium car-
boxymethylcellulose (1500–3000 cps) and polyvinyl alcohol
(80% hydrolyzed, MW 9000–10,000 Da) were obtained from
Sigma–Aldrich India Ltd. (New Delhi, India). All other
chemicals used were of laboratory reagent grade and obtained
from Qualigens Fine Chemicals (Mumbai, India).
2.1. Preparation of spray-dried microparticles
Microparticles were prepared by spray drying (laboratory
spray dryer, Jay Instruments and Systems Pvt. Ltd., India)
aqueous ethanolic solutions (36%, v/v) containing drug (10%,
w/w), leucine (33%, w/w), lactose (37%, w/w) and polymers
(20%, w/w), such as sodium carboxymethyl cellulose (SC),
sodium alginate (SA), polyvinyl alcohol (PA), polyvinylpyrro-
lidone (PP), starch (ST) or carbopol (CP). A control batch
(without polymer) was also prepared using drug (10%, w/w),
leucine (33%, w/w) and lactose (57%, w/w) for comparison.
The spray dryer operating parameters were as follows: inlet
temperature 140 1C, drying air ﬂow rate 28 m3/h, aspirator
pressure 20 bar, feed rate 3 mL/min, outlet temperatures
76 1C. The spray-dried powders were collected from the
product collection chamber. Material adhering to the chamber
lid as well as lower portion of the cyclone chamber taper was
collected using a brush.
2.2. Characterization
2.2.1. Determination of particle morphology and density
Morphology of the microparticles was examined by scanning
electron microscopy (JEOL Ltd., Tokyo, Japan). Dry particles
were attached to specimen stubs using double-sided adhesive
tape and excess particles were blown out using a capillary tube.
Microparticles were imaged using a 5 kV accelerating voltage,
10 mm working distance and emission current of 348 mA by
scanning ﬁelds randomly at several suitable magniﬁcations.
The density of microparticles was assessed by pouring dry
microparticles into a 5 mL graduated cylinder under gravity14.
The ratio of weight to the volume occupied by the powder gives
the bulk density (rb). The cylinder was then tapped onto a level
surface at a height of about 2 cm until no change in volume was
observed. The tap density (rt) and resultant volume was
calculated as the ratio of weight to the tapped volume.
2.2.2. Determination of spray-drying yield and drug
entrapment efﬁciency
The yields of the microparticle were calculated as the percen-
tage ratio of weight of recovered spray-dried powder to the
total amount of dry solids in the initial feed solution.
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was dissolved in 0.1 M HCl. The microparticles were stirred
magnetically to promote swelling and complete dissolution of
the polymer. The obtained solution was ﬁltered through a
0.45 mm syringe ﬁlter. The amount of DX was analysed by
ultraviolet spectrophotometry (JASCO 7800, Tokyo, Japan) at
271.6 nm. The drug entrapment efﬁciency (EE) was calculated
using the following equation:
EE ¼Aactual=Aloading  100% ð1Þ
where Aactual is the actual amount of the drug encapsulated
and Aloading is the amount of drug loading calculated from the
amount of drug added during the manufacturing process. All
the experiments were carried out in triplicate.
2.2.3. Differential scanning calorimetry and
thermogravimetric analyses
The thermal response of each of the powders was analyzed using
a differential scanning calorimeter (DSC, Shimadzu, Japan).
Samples (about 3–5 mg) were hermetically crimp-sealed in
aluminium pans and heated at 30–300 1C at a rate of 10 1C/min.
Thermogravimetric analysis (TGA) was used to determine the
water content in the spray-dried powders. For TGA (TG-DTA,
Setaram Instrumentation, Caluire, France), each sample (about
10 mg) was loaded in an aluminium crucible and heated under a
nitrogen purge at 30–120 1C with a scanning rate of 10 1C/min.
The change in weight with temperature was recorded.
2.2.4. Determination of microparticle aerodynamics
The aerodynamic properties of the microparticles were deter-
mined using an eight stage, nonviable Andersen cascade impac-
tor (ACI) with a preseparator (Graseby-Andersen, Atlanta, GA,
USA). A hard gelatin capsule (size No. 2, Universal capsules,
Mumbai, India) previously stored in a dessicator for at least two
days was manually loaded with the microparticles to approxi-
mately 50% of its volume and placed in a monodose inhaler
(Miat S.p.a Milan, Italy). For each actuation (4 s), the capsule
was pierced and the liberated powder was drawn through the
impactor operated at a continuous air ﬂow rate of 60 L/min
(produced by a vacuum pump connected to the outlet of the
ACI). After 15 actuations per determination, the amount of
microparticles deposited in the device, throat, pre-separator and
each stage of ACI was collected. Under these conditions, the
effective cut off diameters were 8.6, 6.5, 4.4, 3.3, 2.0, 1.1, 0.54 and
0.25 mm for stages 0–7, respectively.
The recovered dose was deﬁned as the total amount of drug
recovered per capsule after each actuation. Emitted dose was
determined as the percent of total powder mass exiting the capsule
(i.e., from throat to ﬁlter in the ACI). The ﬁne particle fraction
(FPF) was deﬁned as the fraction of drug less than 4.7 mm. The
mass median aerodynamic diameter (MMAD) of the micropar-
ticles was determined from the plot of inverse cumulative mass
percentage undersize in each stage against the log effective cut off
diameter of the respective stages. Geometric standard deviation
(GSD) is a measure of the spread of an aerodynamic particle size
distribution. It was calculated as the ratio of diameters at which
84% and 16% of the aerosol mass are contained.
2.2.5. In vitro mucoadhesion
The in vitro mucoadhesion studies were carried out in triplicate
on rat intestinal mucosa by modiﬁcation of a previouslyreported method15. Brieﬂy, a piece of intestinal mucosa
(2 2 cm2) was mounted on to a glass slide using cyanoacrylate
glue. Microparticles (20 mg) were spread uniformly on the
surface of the intestinal mucosa using a monodose insufﬂator
(Miat, Spa, Milan, Italy). This was followed by hydration in a
humidity–temperature control cabinet (Narang Scientiﬁc works
Pvt. Ltd., New Delhi, India) at 80% R.H. and temperature of
2570.5 1C. After 20 min, the mucosal lumen was washed
with physiological saline (pH 7.4) at an angle of 451 using a
peristaltic pump. The washings were dried at 60 1C in a hot air
oven. The ratio of adhered to the applied microparticles was
calculated as percent bioadhesion. The rat intestine was
obtained by decapitating mature albino rats (Approved by
the central animal ethical committee, B.H.U.).2.2.6. Determination of in vitro drug release
In vitro release of DX from the prepared microparticles was
studied in triplicate by diffusion with dialysis bag. The dialysis
membrane (Sigma, thickness 0.025 mm, mol. wt. cutoff 6000–
8000 Da) was cut into equal pieces (6 2.5 cm2) and soaked
in distilled water for 12 h before use. An accurately weighed
quantity of microparticles (equivalent to 10 mg DX) was
suspended in 5 mL of phosphate buffer saline (PBS) pH 7.4
and placed in the dialysis pouch with the two ends ﬁxed by
thread. The pouch was attached to the paddles of USP type II
dissolution tester (Electrolab, TDT 06P model) and put into
the ﬂask containing 500 mL of PBS maintained at 3770.2 1C
and stirred at 50 rpm. Aliquots of samples were withdrawn at
regular time intervals (and fresh PBS replaced) and analyzed
by UV spectrophotometer as described earlier.2.2.7. Determination of formulation cytotoxicity
The in vitro cytotoxicity of microparticles13 was evaluated
using MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay on H1299 mammalian alveolar cells. The
assay is based on the conversion of MTT to formazan (a
soluble purple colored compound) through mitochondrial
activity. Since, this conversion can only be made by living
cells; the quantity of formazan produced is directly correlated
to the number of living cells or cell viability.
The H1299 cells were seeded (5000 cells/well) into a 96-well
plate, incubated overnight at 37 1C and 5% CO2 atmosphere,
and allowed to recover for approximately 24 h. The culture
medium consisted of DMEM, FBS (10%, v/v) with L-glutamine
(2 mM), penicillin (100 units/mL), streptomycin (100 mg/mL)
and amphotericin (50 mg/mL). At 90% conﬂuence, the culture
medium was removed and replaced with 100 mL of the solution
to be tested. The test suspensions were prepared by diluting
sterile, aqueous microparticle suspension with DMEM to
obtain different concentrations (0.01–1.0 mg/mL). The suspen-
sions were sonicated (4 s) and made sterile by passing through
0.22 mm disposable syringe ﬁlters. The cells were then treated
with the test suspensions and SLS (1%, as positive control).
After alveolar cells were incubated with the test suspension for
24, 48 or 72 h, the reaction medium was removed and the cells
were washed twice with DMEM and 100 mL of fresh medium
along with 20 mL of MTT (0.5 mg/mL in DMEM) was added
to each well. After 3 h of incubation the supernatant was
removed and 200 mL of dimethyl sulfoxide (DMSO) was added
to dissolve formazan crystals. Finally, the absorbance was
measured using a microplate spectrophotometer (Microplate
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The results were expressed as the percentage of absorbance of
the treated wells (Abstest) with respect to the untreated wells
(Abscontrol). The untreated cells contained a mixture of only
medium and MTT without cells.
2.3. Statistical analysis
Signiﬁcant differences between formulations were determined
using ANOVA (GraphPad InStat software v 3.06, CA, USA)
followed by Tukey, Kramer, and Bonferroni multiple compar-
isons, and Po0.05 was considered to be signiﬁcant.3. Results and discussion
3.1. Particle morphology
Scanning electron microscopy (SEM) images were used to
visualize the particle diameter, structural and surface mor-
phology of the spray-dried microparticles (Fig. 1). In general,
the micrographs indicate that the dry powders were roughly
spherical in shape and approximate 1-5 mm in diameter. There
were no visible crystalline particles in the micrographs of the
microparticles. The DX loaded microparticles containing SC
and SA were found to be moderately dimpled but spherical in
shape (Fig. 1a and b). The number of indentations was
increased resulting in the formation of corrugated spherical
particles in case of PA and PP containing spray dried powders
(Fig. 1c and d). The DXST microparticles were found to have
a mixture of hollow and collapsed particles resembling a
doughnut shape (Fig. 1e). This may be attributed to the outer
shell formation due to rapid evaporation of the solvent from
the droplet surface during spray drying. But, the solvent
evaporates very slowly inside the droplet and gas expandsFigure 1 Scanning electron microscopy of spray-dried DX loaded
DXSA; (c) DXPA; (d) DXPP; (e) DXST; (f) DXCP. Magniﬁcation:resulting in the build up of internal pressure. Then, the outer
shell becomes thinner to allow faster diffusion of solvent
droplets. As the shell thickness is low and impermeable, the
particles rupture resulting in the formation of hollow particles.
In contrast, the micrographs of microparticles obtained from
spray drying of viscous solutions of CP indicated aggregates of
smooth spherical particles (Fig. 1f). This aggregation may
have occurred during storage. The above results indicate that
the type of polymer used during the preparation of spray-dried
microparticles signiﬁcantly inﬂuenced the particle shape and
morphology. This is in agreement with earlier studies16.3.2. Spray-dried powder characteristics
The spray-drying yield, powder tapped density, drug encapsula-
tion efﬁciency and water content of the different polymer-based
microparticles are shown in Table 1. The yield of the recovered
powder varied considerably. The yield of DXPP formulation was
high (63.04%), whereas DXST exhibited the lowest yield
(50.79%). The DX encapsulation efﬁciency was observed to be
in the range of 75.23%–92.82% of the total drug loading. TGA
results indicated that the moisture content of the powders ranged
2.16–5.03% (w/w). It was observed that the sodium alginate-
based formulations retained more water during spray drying,
thus exhibiting signiﬁcantly greater moisture levels.
Tap density is an important physical attribute of spray-dried
microparticles. The tapped density of the powder is directly
proportional to the aerodynamic diameter17. It was found to vary
from 0.20270.02 to 0.50270.01 g/cm3 and was largely affected by
the particle morphology. The tap density of hollow, collapsed
particles is statistically lower than that of smooth spherical
particles. So, the lightest powder (0.20270.02 g/cm3) was observed
with DXST while tapped densities greater than 0.421 g/cm3 were
observed in DXSC, DXSA and DXCP microparticles.microparticles prepared using different polymers: (a) DXSC; (b)
 2700; bar: 5 mm.
Table 1 Physicochemical characteristics of the spray-dried microparticles (mean7SD, n¼3).
Batcha Yield (%) Tapped density (g/cm3) Encapsulation efﬁciency (%) Water content (%)
DXSC 56.27 0.47170.03 83.7472.31 4.1670.52
DXSA 57.68 0.50270.01 85.4671.11 5.0370.17
DXPA 51.98 0.31070.02 80.1074.53 2.6570.05
DXPP 63.04 0.48870.01 88.7172.01 2.1670.48
DXST 50.79 0.20270.02 75.2371.53 3.1770.86
DXCP 62.34 0.42170.04 92.8273.56 3.8670.52
Data are expressed as mean7SD (standard deviation), n¼3.
aEach batch contains a theoretical drug loading of 10% (w/w).
Figure 2 DSC thermograms of (a) DX; (b) DXSC; (c) DXSA;
(d) DXPA; (e) DXPP; (f) DXST; (g) DXCP.
Figure 3 Percentage mucoadhesion of different polymer-based
microparticles on intestinal mucosa (error bars represent standard
deviation, n¼3). Po0.05 compared with DXSC; #Po0.05
compared with DXSA; þPo0.05 compared with DXPA;
þPo0.05 compared with DXPP; ^Po0.05 compared with DXST.
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The physico-chemical characterisation of microparticles was
performed by DSC analysis. The DSC thermograms of pure
drug (DX) and DX-loaded microparticles are shown in Fig. 2.
Only DX (Fig. 2a) showed a complex transition and a large
endothermic peak due to the melting of the drug at 168.3 1C,
followed by a series of two small exothermic peaks at around
220 1C. Two broad endothermic peaks were observed at
approximately 150 and 220 1C in batches of DXSC and
DXCP (Fig. 2b and g). This may be attributed to glass
transition followed by a peak of crystallisation18. These results
suggest presence of a solid dispersion of drug in the polymer
matrix. A very small and broad endothermic peak around
168 1C was seen in batches of DXPP and DXST (Fig. 2e and f)
while it shifted to approximately 162.3 1C in the calorimetric
curve for DXPA (Fig. 2d). Polymer decomposition peaks were
observed beyond 187 and 220 1C for DXSA (Fig. 2c) and
DXST (Fig. 2f) containing spray-dried microparticles.3.4. In vitro mucoadhesion
Mucoadhesion refers to the attachment of polymers to the mucus
coat on the surface of the epithelium. The pH of mucus in the
lung19 is close to neutral or slightly acidic (pH ¼ 5.5–6.5).
Mucous secreted by the respiratory epithelium is similar to the
intestinal mucosa20. Thus, in vitro mucoadhesion studies were
carried out using rat intestinal mucosa. The results from the
in vitro mucoadhesion studies are shown in Fig. 3. The mechan-
ism of mucoadhesion can be explained in two steps, namely, the
initial contact stage followed by the establishment of the adhesive
interactions21. All the mucoadhesive polymers chosen in this
study are hydrophilic and swellable. When spray dried micro-
particles are spread over the hydrated intestinal mucosa, they
attract water from the mucosal surface and swell (wetting
theory). This results in polymer-mucus interaction, increased
viscosity of this mixture and reduced mucociliary clearance.
Among the spray dried microparticles, the mucoadhesivity
decreased in the following order: DXCP4DXSA4DXSC4
DXPA4DXST4DXPP. In general, the anionic polymers
exhibited greater mucoadhesion than the non-ionic ones. At
similar concentrations (20%, w/w), CP-based microparticles
showed the highest mucoadhesive property (92.09%). CP swells
and forms colloidal gel dispersion by hydration on the mucosa
layer but does not dissolve. The mucoadhesivity of other anionic
polymers (sodium carboxymethyl cellulose and sodium alginate)
was comparatively low (Fig. 2). Batches of DXST and DXPA
showed signiﬁcantly lower mucoadhesion. This may be attrib-
uted to the overwetting of these microparticles resulting in the
wash-induced loss of the less viscous gels. The mucoadhesion of
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hydroxyl and carboxyl groups of the polymer and mucin layers.
3.5. In vitro powder aerosolization
Spray dried microparticles based on different polymers were
evaluated for their aerosolization performance. The results of
the in vitro aerodynamic properties of the microparticles
analyzed in an ACI are summarised in Table 2. Fig. 4 shows
the deposition pattern of different polymer based microparti-
cles on the various stages of the ACI following aerosolization.
The recovered dose ranged 92.1–97.9% of the total loaded
powder weight. The emitted doses varied between 77.9%
(DXST) and 86.8% (DXSA), indicating that a majority of
the spray dried particles were dispersed from the device. As
shown in Fig. 4, less than 15% of the microparticles were
deposited in the preseparator, except with DXST. The
deposition of microparticles was primarily in stages 2, 3
and 4. The FPF consisted of microparticles less than 5 mm in
size. Although the SEM images revealed that the majority of
the particles were in the respirable size range (1–5 mm), the
FPF was found to be less than 60%. This trend in FPF may
be attributed to the strong cohesive and adhesive interparti-
culate forces between the particles during aerosolization22,23.
There was more than a 2-fold difference in the FPF of theTable 2 Aerodynamic properties of the microparticles.
Batch Recovered dose (%) Emitted dose (%)
DXSC 92.171.5 80.270.4
DXSA 93.670.7 86.870.5
DXPA 97.970.6 83.470.2
DXPP 93.271.1 88.370.6
DXST 94.771.3 77.970.1
DXCP 96.172.1 79.170.5
Data are expressed as mean7SD, n¼3.
Figure 4 Deposition proﬁles for spray-dried microparticles showing
each stage of the ACI (effective cut-off diameters are 8.6, 6.5, 4.4, 3.3,
#Po0.01.microparticles depending on polymer content. Signiﬁcantly, a
high FPF value of 55.5% in DXSC suggests that deep lung
penetration of the microparticles is possible. The FPF was
also high for collapsed and hollow particles in DXST
(50.3%). However, only 24.7% FPF was seen in DXCP
due to the considerable aggregation as seen from the SEM
images (Fig. 1f). The MMAD values were within the respir-
able range, i.e., from 3.74 to 5.02 mm except with DXCP. In
general, spherical particles exhibited larger MMAD values.
For DXCP containing microparticles, the mean MMAD was
6.54 mm and GSD was 1.75. It was found to be unsuitable for
deep lung deposition.
3.6. In vitro dissolution
There are currently no ofﬁcial methods for determination of
in-vitro drug release for inhalation products. Researchers have
previously carried out dissolution studies in beakers, in ﬂow-
through cells, and by directly placing the microparticles in the
dissolution medium. These methods often encounter problems
like improper stirring, loss of formulation on sampling and
lack of differentiation between formulations24. In the absence
of an appropriate method, in-vitro dissolution studies were
carried out by dialysis in phosphate buffer in a USP type II
dissolution apparatus. Fig. 5 shows a comparison between theFPF (%) MMAD (%) GSD
55.574.2 4.5670.10 1.5470.12
27.372.3 5.0270.10 1.6870.10
41.673.1 4.0470.10 1.5170.21
47.174.6 3.7470.10 1.4570.07
50.371.1 4.8670.10 2.0170.15
24.773.9 6.5470.10 1.7570.02
microparticles deposited (as percentage of total emitted dose) on
2.0, 1.1, 0.54 and 0.25 mm for stages 0–7, respectively). Po0.05,
Figure 5 Comparison of in vitro release proﬁles of different polymer-based DX-loaded microparticles.
Table 3 Kinetic parameters of drug release for different
polymer-based microparticles.
Batch k (minn) n r2
DXSC 0.162 0.433 0.988
DXSA 0.172 0.451 0.962
DXPA 0.546 0.274 0.997
DXPP 0.242 0.397 0.845
DXST 0.290 0.530 0.940
DXCP 0.200 0.324 0.966
k, kinetic constant; n, diffusion exponent; r2, correlation
coefﬁcient.
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dried microparticles. As expected, the release of pure drug was
rapid and resulted in nearly 100% DX release in approxi-
mately 4 h. The polymer-based spray-dried microparticles
exhibited sustained release characteristics. Previously, research-
ers have reported that when dry hydrophilic polymers contact
physiological ﬂuid the polymer swells to produce a gel diffusion
layer as a barrier to drug release. The DX release from
microparticles was biphasic. Initially, a burst release of nearly
31.05% and 47.86% was seen in batches of DXST and DXPA,
respectively. And at 8 h, greater than 90% of drug was released
in these two batches, indicating that the polymer gel layers were
not sufﬁciently viscous to control the drug release proﬁle.
However, in case of other polymers, the extent of drug release
was statistically slower in the range of 15.61–26.82% within
30 min of release study, indicating no burst release. DXPP was
not able to sustain the drug release beyond 24 h. Less than 50%
of the drug was released in 12.8, 10.6 and 12.2 h in batches of
DXSC, DXSA and DXCP, respectively. At the end of 48 h,
greater than 80% of drug was released in the above mentioned
batches.
To analyse the mechanism and kinetics of drug release25,
the release proﬁles were modelled for correlation to Peppas
equation for the ﬁrst 8 h only. The Peppas equation can be
described as follows:
Mt=M1 ¼ ktn ð2Þ
where Mt/MN is the fraction of drug release. Using the least
squares procedure, the values of n (diffusion exponent), k(kinetic constant) and r2 (correlation coefﬁcient) were esti-
mated (Table 3). In spherical matrices, if nr0.43, a Fickian
diffusion (case-I); 0.4rno0.85, anomalous or non-Fickian
transport; nZ0.85, a case-II transport (zero order) drug
release mechanism dominates. The n value for all the batches
ranges 0.274–0.451 except DXST (n¼0.530). This indicates
Fickian-type of drug diffusion.
3.7. In vitro cytotoxicity
The cytotoxicity results of different polymer-based micropar-
ticles as determined with H1229 cells by incubating with
various concentrations of formulations for 24 and 48 h are
shown in Fig. 6. In general, high cell viability in the range of
123.7–98.8% was observed at concentration of 0.01 mg/mL
Figure 6 H1299 cell viability after (a) 24 and (b) 48 h exposure to
different concentrations of spray-dried microparticles (error bars
represent standard deviation, n¼3).
Mucoadhesive microparticles as potential carriers in inhalation delivery of doxycycline hyclate 525irrespective of the type of polymer in the microparticles. No
signiﬁcant difference (P40.05) in percent cell viability was
observed in batches of DXSC and DXPA on the increasing
concentration by 10- and 100-fold as compared to similar
concentrations of SLS treated cells. Only with the highest
concentration of microparticle (1 mg/mL) was less than 90%
cell viability obtained in DXSA (87.2%), DXST (85.1%) and
DXCP (82.7%) after 48 h of exposure to alveolar cells.4. Conclusions
In this study mucoadhesive microparticles of respirable size
were prepared by using spray drying. The yield of the DXPP
formulation was high (63.04%), whereas DXST exhibited the
lowest yield (50.79%). In order to deposit DX effectively
within the lung, microparticles containing appropriate
mucoadhesive polymers were selected based on their proper-
ties. In general, the dry powders were 1–5 mm in diameter and
varied from roughly spherical (DXSC, DXSA and DXCP),
corrugated (DXPA and DXPP) to hollow particles (DXST).
DXSC, DXSA and DXCP exhibited high encapsulation
efﬁciency and mucoadhesion; however; the water content in
DXSA was very high. The aerosolization property of carbo-
pol-containing microparticles was least due to considerable
aggregation of microparticles. Drug release from these micro-
particles exhibited biphasic Fickian type of diffusion. Only at
the highest concentration of microparticle (1 mg/mL) was less
than 90% cell viability seen with DXSA (87.2%), DXST
(85.1%) and DXCP (82.7%) after 48 h of exposure toalveolar cells. Thus, sodium carboxymethyl cellulose-based
microparticles can serve as an ideal carrier for inhalation
delivery of DX.Acknowledgment
The authors are thankful to Prof. A. N. Misra from the M.S.
University of Baroda in India for providing cell culture
facilities. The ﬁrst author is thankful to UGC in New Delhi
in India for providing Senior Research Fellowship.References
1. He ZX, Wang ZH, Zhang HH, Pan X, Su WR, Liang D, et al.
Doxycycline and hydroxypropyl-beta-cyclodetrin complex in
poloxamer thermal sensitive hydrogel for ophthalmic delivery.
Acta Pharm Sin B 2011;1:254–60.
2. Holmes NE, Charles PGP. Safety and efﬁcacy review of doxycy-
cline. Clin Med Ther 2009;1:471–82.
3. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell
SM. Doxycycline modulates smooth muscle cell growth, migra-
tion, and matrix remodeling after arterial injury. Am J Pathol
2002;160:1089–95.
4. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted
delivery of antibiotics using liposomes and nanoparticles: research
and applications. Int J Antimicrob Agents 2000;13:155–68.
5. Rajinikanth PS, Sankar C, Mishra B. Sodium alginate micro-
spheres of metoprolol tartrate for intranasal systemic delivery:
development and evaluation. Drug Deliv 2003;10:21–8.
6. Sankar C, Mishra M, Mishra B. Design and evaluation of
bioadhesive in-situ gel of ketorolac tromethamine. Chem Pharm
Bull 2008;56:1596–9.
7. Mishra B, Sankar C, Mishra M. Polymer based solutions of
bupranolol hydrochloride for intranasal systemic delivery. J Drug
Target 2011;19:204–11.
8. Sakagami M, Kinoshita W, Sakon K, Sato J, Makino Y.
Mucoadhesive beclomethasone microspheres for powder inhala-
tion: their pharmacokinetics and pharmacodynamics evaluation. J
Control Release 2002;80:207–18.
9. Ventura CA, Tommasini S, Crupi E, Giannone I, Cardile V,
Musumeci T, et al. Chitosan microspheres for intrapulmonary
administration of moxiﬂoxacin: interaction with biomembrane
models and in vitro permeation studies. Eur J Pharm Biopharm
2008;68:235–44.
10. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A.
Inhalable microparticles containing large payload of anti-tubercu-
losis drugs. Eur J Pharm Sci 2007;32:140–50.
11. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan
M, Mahdavi H, et al. Particle size design of PLGA microspheres
for potential pulmonary drug delivery using response surface
methodology. J Microencapsul 2009;26:1–8.
12. Alhusban FA. Seville PC. Carbomer-modiﬁed spray-dried respir-
able powders for pulmonary delivery of salbutamol sulphate.
J Microencapsul 2009;26:444–55.
13. Mishra M, Mishra B. In vitro evaluation of carboxymethylcellulose
based inhable microparticles. J Pharm Pharmac 2010;58:1281–2.
14. Healy AM, McDonald BF, Tajber L, Corrigan OI. Characterisa-
tion of excipient-free nanoporous microparticles (NPMPs) of
bendroﬂumethiazide. Eur J Pharm Biopharm 2008;69:1182–6.
15. Rajinikanth PS, Karunagaran LN, Balasubramaniam J, Mishra
B. Formulation and evaluation of clarithromycin microspheres for
eradication of Helicobacter pylori. Int J Antimicrob Agents
2008;56:1658–64.
16. Nandiyanto BD, Okuyama K. Progress in developing spray-
drying methods for the production of controlled morphology
Madhusmita Mishra, Brahmeshwar Mishra526particles: from the nanometer to submicrometer size ranges. Int
J Antimicrob Agents 2011;22:1–19.
17. Hinds WC. Uniform particle motion. In: Hinds WC, editor. Aerosol
technology-properties, behaviour and measurement of airborne parti-
cles. New York: John Wiley and Sons; 1999. p. 42–74.
18. Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D.
Cospray dried antibiotics for dry powder lung delivery. J Pharm
Sci 2008;97:3356–66.
19. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhe-
sive polymers. Macromol Biosc 2011;11:748–64.
20. Tomashifski JF, Farver CF. Anatomy and histology of the lung.
In: Dail DH, Hammar SP, Cagle PT, editors. Dail and Hammar’s
pulmonary pathology: nonneoplastic lung disease. New York:
Springer; 2008. p. 20–48.
21. Smart JD. The basics and underlying mechanisms of mucoadhe-
sion. Adv Drug Deliv Rev 2005;57:1556–68.22. Louey MD, Van Oort M, Hickey AJ. Aerosol dispersion of
respirable particles in narrow size distributions using drug-alone
and lactose-blend formulations. Pharm Res 2004;21:1207–13.
23. Bosquilon C, Lombry C, Preat V, Vanbever R. Inﬂuence of
formulation excipients and physical characteristics of inhalation
dry powders on their aerosolization performance. J Control
Release 2001;70:329–39.
24. Salama RO, Traini D, Chan HK, Young PM. Preparation and
characterisation of controlled release co-spray dried drug-polymer
microparticles for inhalation 2: evaluation of in vitro release
proﬁling methodologies for controlled release respiratory aerosols.
Eur J Pharm Biopharm 2008;70:145–52.
25. Srikanth MV, Rao NS, Sunil SA, Ram BJ, Kolapalli VR.
Statistical design and evaluation of propranolol HCl gastric
ﬂoating tablet. Acta Pharm Sin B 2012;2:60–9.
